ondansetron has been researched along with Lymphoma, Non-Hodgkin in 7 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The overall incidence of adverse events was similar between the two treatment groups (p > ." | 6.84 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. ( Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017) |
| "We performed a clinical study of a triple-drug combination to evaluate its efficacy to prevent both acute and delayed emesis after high-dose chemotherapy with BEAM (BCNU [carmustine]+etoposide+ARA-C [cytarabine]+melphalan) before hematopoietic stem cell transplantation (HSCT) by comparison with a historical control group of patients treated with dexamethasone (dex) and ondansetron or palonosetron." | 5.15 | A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. ( Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A, 2011) |
| " The overall incidence of adverse events was similar between the two treatment groups (p > ." | 2.84 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. ( Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017) |
| "Ondansetron or droperidol was given intravenously, 30 min prior to the first dose of IL-2 and then every 8 h for the duration of IL-2 treatment." | 2.67 | A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. ( Cole, DJ; Kim, H; Rosenberg, SA; Steinberg, SM; Weber, JS, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Song, Z | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Zhao, K | 1 |
| Zhang, M | 1 |
| Yang, F | 1 |
| Pielichowski, W | 1 |
| Barzal, J | 1 |
| Gawronski, K | 1 |
| Mlot, B | 1 |
| Oborska, S | 1 |
| Wasko-Grabowska, A | 1 |
| Rzepecki, P | 1 |
| Colquhoun, JP | 1 |
| Kim, H | 1 |
| Rosenberg, SA | 1 |
| Steinberg, SM | 1 |
| Cole, DJ | 1 |
| Weber, JS | 1 |
| Fedele, P | 1 |
| Spina, M | 1 |
| Valentini, M | 1 |
| Collini, D | 1 |
| Lucia, C | 1 |
| Manicone, M | 1 |
| Tirelli, U | 1 |
| Wong, ET | 1 |
| Portlock, CS | 1 |
| O'Brien, JP | 1 |
| DeAngelis, LM | 1 |
| Gibbs, SJ | 1 |
| Cassoni, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for ondansetron and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug | 2017 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dex | 2011 |
A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2.
Topics: Adult; Aged; Carcinoma, Renal Cell; Droperidol; Female; Humans; Interleukin-2; Lymphoma, Non-Hodgkin | 1994 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Granisetron; Humans; Lymphoma, AIDS-Related; Lympho | 1995 |
Chemosensitive epidural spinal cord disease in non-Hodgkins lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dox | 1996 |
A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation.
Topics: Administration, Oral; Antiemetics; Bone Marrow Transplantation; Cost-Benefit Analysis; Drug Administ | 1996 |
1 other study available for ondansetron and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
The mark of Zorro.
Topics: Acyclovir; Aged; Anecdotes as Topic; Family Practice; Female; Herpes Zoster Oticus; Humans; Leukemia | 1994 |